Variant report
Variant | nsv968016 |
---|---|
Chromosome Location | chr4:153090362-153094972 |
allele | n/a |
Outlinks | Ensembl   UCSC |
- TF binding region (count:0)
- CpG islands (count:0)
- Chromatin interactive region (count:3)
- LncRNA region (count:0)
- Mature miRNA region (count: 0)
- miRNA target sites (count:0)
No data |
No data |
(count:3 , 50 per page) page:
1
No data |
No data |
No data |
No data |
No. | Variant name | Chromosome position | Chromatin state | Related regulatory elements | Target genes | Extended variants | Associated traits |
---|---|---|---|---|---|---|---|
1 | rs187168619 | chr4:153090376-153090377 | Enhancers Weak transcription Bivalent Enhancer | n/a | n/a | Overlapped CNVs | n/a |
2 | rs6849420 | chr4:153090442-153090443 | Enhancers Weak transcription Bivalent Enhancer | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | mRNA abundance |
3 | rs535874519 | chr4:153090463-153090464 | Enhancers Weak transcription Bivalent Enhancer | n/a | n/a | Overlapped CNVs | n/a |
4 | rs554846790 | chr4:153090466-153090467 | Enhancers Weak transcription Bivalent Enhancer | n/a | n/a | Overlapped CNVs | n/a |
5 | rs72953091 | chr4:153090520-153090521 | Enhancers Weak transcription Bivalent Enhancer | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
6 | rs146444197 | chr4:153090584-153090585 | Enhancers Weak transcription Bivalent Enhancer | n/a | n/a | Overlapped CNVs | n/a |
7 | rs565058845 | chr4:153090587-153090588 | Enhancers Weak transcription Bivalent Enhancer | n/a | n/a | Overlapped CNVs | n/a |
8 | rs17361342 | chr4:153090603-153090604 | Enhancers Bivalent Enhancer Weak transcription | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
9 | rs576653120 | chr4:153090625-153090626 | Enhancers Bivalent Enhancer Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
10 | rs72736218 | chr4:153090695-153090696 | Enhancers Bivalent Enhancer Weak transcription | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
11 | rs11727188 | chr4:153090716-153090717 | Enhancers Bivalent Enhancer Weak transcription | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | mRNA abundance |
12 | rs140928022 | chr4:153090732-153090733 | Enhancers Bivalent Enhancer Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
13 | rs541897518 | chr4:153090737-153090738 | Enhancers Bivalent Enhancer Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
14 | rs192459056 | chr4:153090771-153090772 | Enhancers Bivalent Enhancer Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
15 | rs532194647 | chr4:153090834-153090835 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
16 | rs79580320 | chr4:153090867-153090868 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
17 | rs183356830 | chr4:153090887-153090888 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
18 | rs564636383 | chr4:153090932-153090933 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
19 | rs531820930 | chr4:153090938-153090939 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
20 | rs187601700 | chr4:153091026-153091027 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
21 | rs562492233 | chr4:153091050-153091051 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
22 | rs529684214 | chr4:153091054-153091055 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
23 | rs371054863 | chr4:153091177-153091178 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
24 | rs534553777 | chr4:153091191-153091192 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
25 | rs547816467 | chr4:153091203-153091204 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
26 | rs200162016 | chr4:153091238-153091239 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
27 | rs566408517 | chr4:153091282-153091283 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
28 | rs375152414 | chr4:153091305-153091306 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
29 | rs558261463 | chr4:153091309-153091310 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
30 | rs2897464 | chr4:153091323-153091324 | Weak transcription | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | mRNA abundance |
31 | rs143327075 | chr4:153091341-153091342 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
32 | rs146728282 | chr4:153091343-153091344 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
33 | rs537650466 | chr4:153091392-153091393 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
34 | rs190712939 | chr4:153091396-153091397 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
35 | rs2897463 | chr4:153091443-153091444 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
36 | rs370080139 | chr4:153091446-153091447 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
37 | rs535816681 | chr4:153091477-153091478 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
38 | rs554178763 | chr4:153091670-153091671 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
39 | rs75939308 | chr4:153091683-153091684 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
40 | rs150389294 | chr4:153091684-153091685 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
41 | rs182560210 | chr4:153091685-153091686 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
42 | rs138133349 | chr4:153091761-153091762 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
43 | rs187222050 | chr4:153091814-153091815 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
44 | rs374351654 | chr4:153091827-153091828 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
45 | rs373386974 | chr4:153091831-153091832 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
46 | rs79901760 | chr4:153091863-153091864 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
47 | rs547905959 | chr4:153091885-153091886 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
48 | rs149147910 | chr4:153091898-153091899 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
49 | rs527301045 | chr4:153091944-153091945 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
50 | rs192155470 | chr4:153091952-153091953 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
Disease | PMID | Source |
---|---|---|
Acute lymphoblastic leukemia | 22237106 | CNVD |
Glioblastoma multiforme | 21080181 | CNVD |
Esophageal squamous carcinoma | 21637470 | CNVD |
Chordoma | 21602918 | CNVD |
HIV/AIDS | 22032296 | CNVD |
Medulloblastoma | 21979893 | CNVD |
Neuroblastoma | 18923191 | CNVD |
Breast cancer | 21858162 | CNVD |
Small bowel adenocarcinoma | 21586687 | CNVD |
Gastric cancer | 21586687 | CNVD |
Basal cell lymphoma | 16317097 | CNVD |
Diffuse large b-cell lymphoma | 16317097 | CNVD |
Breast cancer | 17603634 | CNVD |
Acute lymphoblastic leukemia | 20067559 | CNVD |
Esophageal squamous carcinoma | 18350619 | CNVD |
Colorectal cancer | 19359472 | CNVD |
Malignant mesothelioma | 18160781 | CNVD |
Medulloblastoma | 18056178 | CNVD |
Multiple myeloma | 17077331 | CNVD |
Pleural malignant mesothelioma | 18160781 | CNVD |
Primary mediastinal b-cell lymphoma | 17728785 | CNVD |
Oral squamous cell carcinoma | 17134496 | CNVD |
4q-syndrome | 17576883 | CNVD |
Cancer | 21637783 | CNVD |
Non-syndromic sensorineural hearing loss | 18471307 | CNVD |
Colorectal cancer | 20709793 | CNVD |
Muscular dystrophy | 21149563 | CNVD |
Endometrial cancer | 22040021 | CNVD |
Breast cancer | 21264507 | CNVD |
Glioblastoma multiforme | 19960244 | CNVD |
Glioblastoma multiforme | 17387387 | CNVD |
Hepatocellular carcinoma | 22174799 | CNVD |
Liposarcoma | 21253554 | CNVD |
Oligodendroglial tumors | 17285580 | CNVD |
Cervical cancer | 21062161 | CNVD |
Metanephric adenoma | 20802469 | CNVD |
Breast cancer | 16608533 | CNVD |
Lung cancer | 19208797 | CNVD |
Wilms tumour | 21544195 | CNVD |
Lung cancer | 18438408 | CNVD |
Cancer | 22429812 | CNVD |
Acute lymphoblastic leukemia | 20435627 | CNVD |
Cancer | 21183584 | CNVD |
primary effusion lymphomas | 17116491 | CNVD |
Breast cancer | 16272173 | CNVD |
Splenic marginal zone lymphoma | 21957467 | CNVD |
Breast cancer | 17133270 | CNVD |
High-grade prostatic intraepithelial neoplasia | 16573809 | CNVD |
Endometrioid adenocarcinoma | 16974079 | CNVD |
Congenital anomalies of the kidney and urinary tract | 20505237 | CNVD |
Breast cancer | 17393978 | CNVD |
Esophageal cancer | 21851588 | CNVD |
Testicular germ cell tumor | 18059402 | CNVD |
Ovarian cancer | 22174824 | CNVD |
Olfactory neuroblastoma | 18408657 | CNVD |
Breast cancer | 21785460 | CNVD |
Hodgkin''s lymphoma | 18641027 | CNVD |
Hodgkin''s lymphoma | 17606441 | CNVD |
small cell lung cancer | 20016488 | CNVD |
T-cell prolymphocytic leukemia | 17713554 | CNVD |
Congenital diaphragmatic hernia | 21085971 | CNVD |
Ewing''s sarcoma | 17952124 | CNVD |
Breast cancer | 21633010 | CNVD |
Breast cancer | 21364760 | CNVD |
T-cell prolymphocytic leukemia | 19278963 | CNVD |
Myelofibrosis | 22110671 | CNVD |
Acute lymphoblastic leukemia | 17443227 | CNVD |
Non-small cell lung cancer | 21829676 | CNVD |
Breast cancer | 17588203 | CNVD |
T-cell acute lymphoblastic leukemia | 18185524 | CNVD |
Invasive pancreatic ductal carcinoma | 16982739 | CNVD |
Pancreatic ductal adenocarcinoma | 19077451 | CNVD |
Non-syndromic sensorineural hearing loss | 22037309 | CNVD |
No. | Chromosome Location | Chromatin state | Cell line | Tissue |
---|---|---|---|---|
1 | chr4:153078000-153090600 | Weak transcription | hESC Derived CD56+ Ectoderm Cultured Cells | ES cell derived |
2 | chr4:153086000-153090400 | Weak transcription | iPS DF 6.9 Cell Line | embryonic stem cell |
3 | chr4:153086000-153094400 | Weak transcription | Aorta | Aorta |
4 | chr4:153086600-153090600 | Weak transcription | H9 Cell Line | embryonic stem cell |
5 | chr4:153086800-153090400 | Weak transcription | HUES6 Cell Line | embryonic stem cell |
6 | chr4:153087200-153090600 | Weak transcription | iPS-20b Cell Line | embryonic stem cell |
7 | chr4:153090000-153090800 | Bivalent Enhancer | Mesenchymal Stem Cell Derived Chondrocyte Cultured Cells | embryonic stem cell |
8 | chr4:153090200-153090600 | Enhancers | ES-UCSF4 Cell Line | embryonic stem cell |
9 | chr4:153090200-153091000 | Enhancers | ES-I3 Cell Line | embryonic stem cell |
10 | chr4:153090200-153091000 | Enhancers | H1 Cell Line | embryonic stem cell |
11 | chr4:153090200-153091000 | Enhancers | HUES48 Cell Line | embryonic stem cell |
12 | chr4:153090200-153091000 | Enhancers | HUES64 Cell Line | embryonic stem cell |
13 | chr4:153090200-153091000 | Enhancers | iPS-18 Cell Line | embryonic stem cell |
14 | chr4:153090200-153091200 | Enhancers | iPS-15b Cell Line | embryonic stem cell |
15 | chr4:153090400-153090600 | Enhancers | iPS DF 6.9 Cell Line | embryonic stem cell |
16 | chr4:153090400-153091000 | Enhancers | HUES6 Cell Line | embryonic stem cell |
17 | chr4:153090600-153091000 | Enhancers | H9 Cell Line | embryonic stem cell |
18 | chr4:153090600-153091000 | Enhancers | hESC Derived CD56+ Ectoderm Cultured Cells | ES cell derived |
19 | chr4:153090600-153091200 | Enhancers | iPS-20b Cell Line | embryonic stem cell |
20 | chr4:153092200-153092600 | Enhancers | Adipose Derived Mesenchymal Stem Cell Cultured Cells | ES cell derived |
21 | chr4:153094800-153095600 | Bivalent Enhancer | H1 Derived Mesenchymal Stem Cells | ES cell derived |